Mix-and-match vax effective against COVID: Lancet

Since the use of AstraZeneca’s vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.

“Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one,” said Peter Nordstrom, a professor at Umea University, Sweden.

“However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses,” Nordstrom said. The study, published in The Lancet Regional Health - Europe journal on Monday, is based on nationwide registry data from the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden.

In the main analysis, about 700,000 individuals were included. During a 2.5-month average follow-up period after the second dose, the study showed a 67 per cent lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots.

There was a 79 per cent lower risk of infection for AstraZeneca and Moderna vaccine shots, compared to unvaccinated individuals, the researchers said. For people having received two doses of the AstraZeneca vaccine, known as Covishield in India, the risk reduction was 50, they said. These risk estimates were observed after accounting for differences regarding date of vaccination, age and other risk factors for COVID-19.